Zogenix (ZGNX) Tops Q1 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Zogenix (ZGNX) Tops Q1 EPS by 2c

Zogenix Provides Corporate Update and Reports First Quarter 2017 Financial Results

May 4, 2017 4:01 PM EDT

Completed Enrollment of Study 1, First Phase 3 Clinical Trial of ZX008 in Dravet Syndrome; 

Top-Line Results Expected in Third Quarter 2017

IND Accepted by FDA for Phase 3 Clinical Trial of ZX008 in Lennox Gastaut Syndrome

Company will host a conference call today at 4:30 p.m. EDT/1:30 p.m. PDT

EMERYVILLE, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today... More